Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA 1c
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Guangxin Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Blood Glucose Self-Monitoring, Glycemic Control. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, Health Economics Association of Guangdong Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To evaluate the long‐term cost‐effectiveness of continuous glucose monitoring (CGM) versus self‐monitoring of blood glucose (SMBG) in Chinese adults with uncontrolled type 2 diabetes (T2D) to inform optimal disease management and reimbursement policies.
Methods
The United Kingdom Prospective Diabetes Study Outcomes Model version 2 was used to simulate 30‐year cost and health outcomes for cohorts with baseline HbA 1c levels of 7.70%, 8.70%, 9.70%, and 10.70%. Clinical efficacy data were derived from meta‐analyses. A cost‐effectiveness analysis from China's healthcare perspective referenced a $40 344 per quality‐adjusted life year (QALY) willingness‐to‐pay (WTP) threshold, equal to three times China's per capita gross domestic product (GDP). Sensitivity and scenario analyses addressed model uncertainty and determined annual CGM cost thresholds.
Results
For baseline HbA 1c levels of 7.70%–10.70%, CGM yielded incremental cost‐effectiveness ratios (ICERs) of $29 428 to $38 819 per QALY gained, respectively—all below the WTP threshold. Higher baseline HbA 1c was associated with greater cost‐effectiveness. Sensitivity analyses showed CGM utility benefits and device costs were key drivers. All cohorts demonstrated >96% cost‐effectiveness probability. Annual CGM cost thresholds for cost‐effectiveness ranged from $1920 to $2316 depending on baseline HbA 1c levels of 7.70%–10.70%.
Conclusions
CGM represents a cost‐effective intervention for Chinese adults with uncontrolled T2D, demonstrating enhanced economic value in populations with elevated baseline HbA 1c levels. Implementing risk‐stratified reimbursement policies coupled with price negotiations aligned with evidence‐based cost thresholds ($1920–$2316 annually), may optimize healthcare resource allocation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
- Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Endocrinology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
- School of Pharmacy, Clinical Pharmacy Department, Guangdong Pharmaceutical University, Guangzhou, China.
ORCID-Profile: Sha Lai
Förderung
- National Key Clinical Specialty Discipline Construction Program of China
- Health Economics Association of Guangdong Province
Zitieren
APA
Han, G., Zhang, X., Ye, Y., Wang, C., Hu, L., Wu, H., Qiu, Z., Yuan, F., Chen, J., & Lai, S. (2026). Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA 1c. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70333
Vancouver
Han G, Zhang X, Ye Y, Wang C, Hu L, Wu H, et al. Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA 1c. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70333
BibTeX
@article{Han2026,
author = {Han, Guangxin and Zhang, Xiaoning and Ye, Yubing and Wang, Changsheng and Hu, Li and Wu, Hanbiao and Qiu, Zhikun and Yuan, Fang and Chen, Jisheng and Lai, Sha},
title = {Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA 1c},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70333}
}
EUVIMED